A marijuana fund from Canadian financial firm Purpose Investments provides returns of over 50 percent in one year, credited to active management.

On Tuesday (February 26), it was revealed the Purpose Marijuana Opportunities Fund (NEO:MJJ) has made returns for investors of 53.43 percent on a one-year basis since its inception on January 31, 2018.


This fund differs from a variety of other publicly available exchange-traded funds (ETFs) due to its management ruling.

Greg Taylor, chief investment officer of Purpose Investments and portfolio manager of the fund, credited the returns to the ability of the fund to pursue “thematic opportunities, such as the rapid product innovation happening now in the US.”

Taylor also highlighted his fund is capable of participating in companies at a growing stage before an initial public offering (IPO).

According to Purpose Investments, the volatile state of marijuana investing has led to “periods of speculative mania,” which may continue as Canadian cannabis firms are still expanding.

As part of a rush in Canadian cannabis stocks in the public markets, ETFs have appeared in the space to try and offer a simplified method of investment.

ETFs that offer a collection of pot stocks end up moving with the market volatility that precedes the marijuana industry, despite its quarterly rebalances.

“Passive investing in a new industry, such as marijuana, often means chasing or missing opportunities because the indexes are rebalancing much more slowly than the market itself is moving,” Taylor said.

Purpose Investments compared its fund to the Solactive North American Marijuana Index, which tracks a “basket of North American publicly listed companies with significant business activities in the marijuana industry.”

Other marijuana ETFs in the public markets include: the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), the Horizons Emerging Marijuana Growers Index ETF (NEO:HMJR) and the Evolve Marijuana ETF (TSX:SEED).

Similar to Purpose Marijuana Opportunities Fund, the Evolve’s fund is an actively monitored ETF. This fund costs investors a management fee of 0.75 percent, the same as the Purpose Investments fund.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less